Provided by Tiger Fintech (Singapore) Pte. Ltd.

TransCode Therapeutics Inc.

11.10
-0.0500-0.45%
Volume:14.21K
Turnover:157.73K
Market Cap:9.25M
PE:-0.02
High:11.59
Open:11.22
Low:10.84
Close:11.15
Loading ...

Transcode Therapeutics Inc trading resumes

TIPRANKS
·
23 Jul

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Scientific Advisory Board to Drive RNA Oncology Advancements

Reuters
·
28 May

Transcode Therapeutics Inc trading halted, news pending

TIPRANKS
·
15 May

Transcode Therapeutics completes dosing of patients in Phase 1a cancer trial

TIPRANKS
·
08 May

TransCode Therapeutics Faces Nasdaq Delisting Risk

TIPRANKS
·
08 May

TransCode Therapeutics Announces Reverse Stock Split

TIPRANKS
·
06 May

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

PR Newswire
·
06 May

Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday

Benzinga
·
05 May

BRIEF-Transcode Therapeutics Announces 1-For-28 Reverse Stock Split

Reuters
·
03 May

TransCode Therapeutics to Implement 1-for-28 Reverse Stock Split

MT Newswires Live
·
03 May

Transcode Therapeutics announces 1-for-28 reverse stock split

TIPRANKS
·
03 May

TransCode Therapeutics Approves 1-for-28 Reverse Stock Split to Meet Nasdaq Requirements

Reuters
·
03 May

TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

TIPRANKS
·
02 May

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

PR Newswire
·
01 May

EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug

Benzinga
·
01 May

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

PR Newswire
·
22 Apr

Transcode Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
16 Apr

TransCode Therapeutics Delays Annual Report Filing

TIPRANKS
·
01 Apr

TransCode Therapeutics Starts Dosing for Experimental Cancer Treatment in Early Trial

MT Newswires Live
·
28 Mar

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

PR Newswire
·
28 Mar